Connect Sign In
Atypical cell-free DNA results frequently indicate clinically relevant diagnoses and offer important clues for follow-up diagnostic testing.
ARUP Laboratories’ Infectious Disease Test Positivity Trends Dashboard now includes Cyclospora data to help clinicians and public health professionals monitor the rising cyclosporiasis outbreak.
ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry characterizes neoplastic populations with greater confidence and sensitivity, while minimizing specimen volume requirements.
Newly introduced federal legislation would modernize oversight of lab-developed tests under the Clinical Laboratory Improvement Amendments but support innovation, transparency, and patient access.
ARUP’s new online dashboard offers clinicians and laboratories unprecedented visibility into pathogen activity through positive test result trends derived from deidentified data.
ARUP’s Innovation Central Laboratory will serve as an ecosystem for validating technologies and accelerating next generation diagnostics from concept to commercialization.
ARUP is the first U.S. lab to validate Rarity Bioscience’s ultrasensitive superRCA™ assay, which advances high-precision mutation detection and supports innovation in clinical and trial settings.
In his new role, Adam Barker, PhD, will lead operational innovation to support ARUP’s growth while maintaining the highest quality.
RIDGEWATER, N.J.—Recordati Rare Diseases Inc. today announced the presentation of new data detailing advances in the understanding of Castleman disease (CD), a group of rare immune system disorders characterized by abnormal lymph node enlargement and systemic inflammatory symptoms that can be…
The RESULTS Act offers meaningful reform to a flawed system and will ultimately benefit patients, support innovation, and create stability within the clinical laboratory community.
